NASDAQ$BCAB
Bioatla Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
BioAtla reported its financial results for the first quarter ended March 31, 2025, showing a reduced net loss and decreased operating expenses compared to the same period in 2024.
BioAtla reported a net loss of $15.3 million for Q1 2025, an improvement from the $23.2 million net loss in Q1 2024. This was primarily driven by a decrease in research and development expenses, which fell to $12.4 million from $18.9 million in the prior year, as the company completed Phase 2 trials and focused on prioritized programs. The company's cash balance is projected to fund operations beyond key clinical readouts in 1H 2026.
- Net loss significantly decreased to $15.3 million in Q1 2025 from $23.2 million in Q1 2024.
- Research and development expenses decreased by $6.5 million due to lower clinical development expenses and restructuring.
- Cash and cash equivalents stood at $32.4 million as of March 31, 2025, down from $49.0 million at the end of 2024.
- The company expects cost reductions to provide sufficient runway to fund operations and achieve key clinical readouts in the first half of 2026.
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
BioAtla expects continued decreases in R&D expenses for the remainder of 2025 due to restructuring and completion of Phase 2 trials. The current cash balance is projected to fund operations beyond key clinical readouts in the first half of 2026.
Tailwinds
- R&D expenses are expected to continue decreasing for the remainder of 2025.
- Cost reductions from resource realignment are expected to provide sufficient runway to fund operations.
- Key clinical readouts are anticipated in the first half of 2026.
- The company is focusing on its two internal priority programs.
- Potential new partnerships could provide additional funding.
Headwinds
- The company will need additional funding to continue development of its CAB technology platform and product candidates.
- Potential delays in clinical and preclinical trials could impact timelines.
- Uncertainties inherent in research and development, including meeting clinical endpoints and regulatory approvals.
- Regulatory authorities may not be satisfied with study designs or results.
- Dependence on third parties for manufacturing, supply, and clinical trial conduct poses risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro